Clinical Trial Update: Efficacy and Safety of CDK4/6 Inhibitors Combined With Endocrine Therapy in HR+/HER2- Neoadjuvant Therapy for Early Breast Cancer [Phase 2]

View source ↗

Summary

This Phase 2 trial investigates the efficacy and safety of CDK4/6 inhibitors combined with endocrine therapy as neoadjuvant treatment for HR+/HER2- early breast…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Snippet

Sponsor: Xinhong Wu, PhD | Conditions: HR+/HER2- Breast Cancer | Phase 2 | Status: ACTIVE_NOT_RECRUITING